Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

NCT02526017 is registered in ClinicalTrials.gov with Five Prime Therapeutics, Inc. as lead sponsor.

NCT NCT02526017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02526017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Lead sponsor
Five Prime Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 8, 2015
Completion date
November 18, 2019
Enrollment
313 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, head and neck cancer, malignant glioma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, renal cell carcinoma